Business Context and Reporting Period
This Form 8-K was filed by Heatwurx, Inc. on September 27, 2013. The filing discloses a significant management transition under Item 7.01 (Regulation FD Disclosure). Note: The request metadata references "Processa Pharmaceuticals, Inc.," but the filing text explicitly identifies the registrant as Heatwurx, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
- Executive Departure: Stephen Garland, the current President and Chief Executive Officer, intends to assist in seeking a replacement for his role as principal executive officer by December 31, 2013.
- Board Retention: Mr. Garland intends to remain as a director of the Company following his departure as CEO.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or specific risk factors beyond the operational uncertainty inherent in a CEO transition. The information is furnished pursuant to Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the timeline for the appointment of a new CEO (targeted by December 31, 2013).
- Confirm the specific terms of Stephen Garland's continued role as a director.
- Review the attached press release (Exhibit 99.1) for additional details on the transition plan.
- Check subsequent filings for the official appointment of the new principal executive officer.